FASTURTEC POWDER FOR SOLUTION FOR INFUSION 1.5 mgvial Singapore - English - HSA (Health Sciences Authority)

fasturtec powder for solution for infusion 1.5 mgvial

sanofi-aventis singapore pte. ltd. - rasburicase - injection, powder, for solution - 1.5 mg/vial - rasburicase 1.5 mg/vial

Nature’s Own Vitamin B5 250mg Australia - English - Department of Health (Therapeutic Goods Administration)

nature’s own vitamin b5 250mg

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - calcium pantothenate -

HEXAXIM DTPa-hepB-IPV-Hib Suspension for injection in pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

hexaxim dtpa-hepb-ipv-hib suspension for injection in pre-filled syringe

sanofi-aventis australia pty ltd - tetanus protein, quantity: 22 microgram; haemophilus type b polysaccharide, quantity: 12 microgram; pertussis toxoid, quantity: 25 microgram; diphtheria toxoid, quantity: 20 iu; poliovirus, quantity: 8 dagu; poliovirus, quantity: 40 dagu; tetanus toxoid, quantity: 40 iu; pertussis filamentous haemagglutinin, quantity: 25 microgram; poliovirus, quantity: 32 dagu; hepatitis b surface antigen, quantity: 10 microgram - injection, suspension - excipient ingredients: sucrose; monobasic potassium phosphate; dibasic sodium phosphate heptahydrate; water for injections; aluminium hydroxide hydrate; trometamol; tyrosine; arginine hydrochloride; histidine; isoleucine; leucine; lysine hydrochloride; phenylalanine; threonine; tryptophan; valine; cystine; methionine - hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive infections caused by haemophilus influenzae type b. use of this vaccine should be in accordance with the national recommendation as per the current immunisation handbook.

EVOLTRA clofarabine 20 mg/20 mL concentrated solution for infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

evoltra clofarabine 20 mg/20 ml concentrated solution for infusion vial

sanofi-aventis australia pty ltd - clofarabine, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium chloride - treatment of acute lymphocytic leukaemia (all) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens. this use is based on the induction of complete responses.

KARVEZIDE 300/25 irbesartan 300mg and hydrochlorothiazide 25mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

karvezide 300/25 irbesartan 300mg and hydrochlorothiazide 25mg tablet blister pack

sanofi-aventis australia pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: iron oxide red; iron oxide yellow; croscarmellose sodium; silicon dioxide; carnauba wax; lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 3350; iron oxide black - karvezide is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

AVAPRO HCT 300/25 irbesartan 300mg and hydrochlorothiazide 25mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

avapro hct 300/25 irbesartan 300mg and hydrochlorothiazide 25mg tablet blister pack

sanofi-aventis australia pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: silicon dioxide; microcrystalline cellulose; pregelatinised maize starch; lactose monohydrate; iron oxide yellow; magnesium stearate; carnauba wax; croscarmellose sodium; iron oxide red; titanium dioxide; hypromellose; macrogol 3350; iron oxide black - avapro hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

AVAPRO HCT 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

avapro hct 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; croscarmellose sodium; hypromellose; carnauba wax; magnesium stearate; lactose monohydrate; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 3000 - avapro hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

AVAPRO HCT 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

avapro hct 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: carnauba wax; lactose monohydrate; magnesium stearate; hypromellose; croscarmellose sodium; silicon dioxide; microcrystalline cellulose; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 3000 - avapro hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

KARVEZIDE 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

karvezide 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; lactose monohydrate; silicon dioxide; croscarmellose sodium; magnesium stearate; carnauba wax; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 3000 - karvezide is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

KARVEZIDE 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

karvezide 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; carnauba wax; magnesium stearate; silicon dioxide; microcrystalline cellulose; hypromellose; lactose monohydrate; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 3000 - karvezide is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.